|
EHHADH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.58179999999653E-05 |
| Normal-vs-Stage3 |
1.64768199084619E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
5.897800E-02 |
| Stage1-vs-Stage3 |
1.706960E-01 |
| Stage1-vs-Stage4 |
4.06860000000675E-05 |
| Stage2-vs-Stage3 |
1.145800E-02 |
| Stage2-vs-Stage4 |
5.63559999999796E-05 |
| Stage3-vs-Stage4 |
8.204800E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.49280000028007E-07 |
| Normal-vs-Asian |
5.22426546467614E-12 |
| Caucasian-vs-AfricanAmerican |
6.553200E-01 |
| Caucasian-vs-Asian |
6.744800E-01 |
| AfricanAmerican-vs-Asian |
4.787400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.50910403565285E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.805200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
4.12148093431597E-12 |
| Normal-vs-Age(81-100Yrs) |
6.244300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.273600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.879400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.610000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.206200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.175400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.533400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.475700E-02 |
| Classical-VS-Follicular |
2.738700E-03 |
| Classical-VS-Other |
6.257000E-01 |
| Classical-VS-Normal |
1.71385128311385E-12 |
| Tall-VS-Follicular |
1.800620E-04 |
| Tall-VS-Other |
7.440800E-01 |
| Tall-VS-Normal |
2.28705943072782E-14 |
| Follicular-VS-Other |
1.823820E-01 |
| Follicular-VS-Normal |
1.53090000010181E-07 |
| Other-VS-Normal |
1.818210E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.10782519111308E-15 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
7.85910000000722E-05 |
|
|
